Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA) Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report ...
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Global Clinical Trials Review, 2025" clinical trials has been added to ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Latest analysis reveals key trends and opportunities in the Multiple System Atrophy (MSA) market, highlighting advancements in treatment options. BURLINGAME, CA, UNITED STATES, October 30, 2024 ...
MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback